Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab +/- Pomalidomide and Dexamethasone in RRMM
NCT02616640Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2016
- Primary completion
- Nov 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 7
01
Overview
Phase 1, open-label trial of durvalumab in multiple myeloma (MM) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Dose-limiting Toxicities at 1 month. Started Jan 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02616640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616640.